Search

Your search keyword '"Wohlfarth K"' showing total 150 results
Start Over Author "Wohlfarth K"
150 results on '"Wohlfarth K"'

25. BoNT/D is effective in humans – but with higher dosing and shorter duration than BoNT/A

Author

Wohlfarth, K, primary, Fiedler, T, additional, Kollewe, K, additional, Wegner, F, additional, Weisemann, J, additional, Adeli, G, additional, Alvermann, S, additional, Böselt, S, additional, Escher, C, additional, Garde, N, additional, Gingele, S, additional, Kaehler, SB, additional, Karatschai, R, additional, Krüger, T, additional, Schmidt, T, additional, Sikorra, S, additional, Tacik, P, additional, Wollmann, J, additional, Dengler, R, additional, Bigalke, H, additional, and Rummel, A, additional

Published
2014
Full Text
View/download PDF

34. Introductory Experience with the Continuous Glucose Monitoring System (CGMS®; Medtronic Minimed®) in Detecting Hyperglycemia by Comparing the Self-Monitoring of Blood Glucose (SMBG) in Non-Pregnant Women and in Pregnant Women with Impaired Glucose Tolerance and Gestational Diabetes

Author

Bühling, K., primary, Kurzidim, B., additional, Wolf, C., additional, Wohlfarth, K., additional, Mahmoudi, M., additional, Wäscher, C., additional, Siebert, G., additional, and Dudenhausen, J., additional

Published
2004
Full Text
View/download PDF

40. Letters to the Editor

Author

Krack, Paul, primary, Deuschl, GÜNther, additional, Benecke, Reiner, additional, Ceballos-Baumann, Andres O., additional, Marion, Marie-HéLèNe, additional, Delhomme, Rue LéOn, additional, Oertel, Wolfgang H., additional, Poewe, Werner, additional, Wohlfarth, K., additional, Göschel, H., additional, Frevert, J., additional, Dengler, R., additional, Bigalke, H., additional, Montagna, Pasquale, additional, Lugaresi, Elio, additional, Fahn, Stanley, additional, Evidente, Virgilio Gerald H., additional, and Gwinn, Katrina A., additional

Published
1998
Full Text
View/download PDF

50. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?

Author

Wohlfarth K, Sycha T, Ranoux D, Naver H, and Caird D

Abstract

BACKGROUND: The units of different preparations of botulinum neurotoxin type A (BoNT-A) have different potencies, and dosing recommendations for each product are not interchangeable. Historically, there has been debate concerning the dose-equivalence ratio that should be used in clinical practice. METHODS: Published evidence was considered to establish an appropriate dose-conversion ratio for the two main commercially available preparations of BoNT-A--Dysport (Dp) and Botox (Bx). RESULTS: Four key areas of evidence were identified: nonclinical and preclinical studies; studies exploring the diffusion characteristics and effects of complexing proteins; comparative experimental data from human studies; and clinical studies. Nonclinical data indicate that the principal reasons for differences in unit potency between the two products are dilution artefacts in the mouse assay. Use of saline as a diluent, at high dilutions, results in significant loss of potency in the Bx assay, whereas use of gelatin phosphate buffer in the Dp assay procedure protects the toxin during dilution. The published data on mouse assays show a Dp : Bx unit ratio range of 2.3-2.5 : 1 in saline and 1.8-3.2 : 1 in gelatin phosphate buffer. Data indicate that complexing proteins or size of the complex, which is highly pH sensitive, play no role in toxin diffusion and that Dp and Bx have similar diffusion characteristics when used at comparable doses. Randomized, controlled clinical studies indicate that 3 : 1 is more appropriate than 4 : 1, but the two products are not equivalent at this ratio. Comparative human experimental studies using the extensor digitorum brevis test, facial lines and anhidrotic action halo tests support dose-conversion ratios less than 3 : 1. LIMITATIONS: Data comparing dose equivalence ratios from the non-clinical setting should be extrapolated into the clinical setting with some caution. CONCLUSIONS: Dose-conversion ratios between Dp and Bx of 4 : 1 and greater are not supported by the recent literature. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results